Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines announced pivotal Phase 3 results for daraxonrasib in metastatic pancreatic cancer, showing a 60% reduction in the risk of death compared to standard chemotherapy. The trial met all primary and key secondary endpoints, with median overall survival of 13.2 months versus 6.7 months for chemo, and significantly improved progression-free survival and quality of life metrics. Results were published in The New England Journal of Medicine and presented as a plenary session at ASCO.
Key figures
- Drug Name
- daraxonrasib
- Phase Of Trial
- Phase 3
- Hazard ratio os
- 0.4
- Hazard ratio pfs
- 0.49
- Trial enrollment
- 500
- Median os chemo months
- 6.7
- Median pfs chemo months
- 3.6
- Risk reduction death pct
- 60
- Grade 3 plus trae chemo pct
- 57.5
- Median os daraxonrasib months
- 13.2
- Discontinuation rate chemo pct
- 11.2
- Median pfs daraxonrasib months
- 7.2
- Objective response rate chemo pct
- 11.2
- Grade 3 plus trae daraxonrasib pct
- 43.6
- Discontinuation rate daraxonrasib pct
- 1.2
- Objective response rate daraxonrasib pct
- 31.6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.